IEXIndustrials · Specialty Industrial MachineryThe 15 Wall Street analysts covering IDEX Corp. hold a median 12-month price target of $258 — +10.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores IDEX Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (96): Analysts have, on balance, been raising their forecasts.
Value (53): The shares cost a lot relative to the profits and assets behind them.
Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IEX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.1% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Mizuho | Upgrade | Outperform | $210 → $280 |
| 6 Aug 2026 | Argus Research | Maintains | Buy | $250 → $260 |
| 6 Aug 2026 | DA Davidson | Maintains | Neutral | $230 → $240 |
| 30 July 2026 | Citigroup | Maintains | Buy | — |
| 30 July 2026 | Citigroup | Maintains | Buy | $252 → $269 |
| 30 July 2026 | RBC Capital | Maintains | Outperform | — |
| 30 July 2026 | RBC Capital | Maintains | Outperform | $261 → $280 |
| 30 July 2026 | Stifel | Maintains | Buy | $257 → $268 |
| 30 July 2026 | Stifel | Maintains | Buy | — |
| 30 July 2026 | TD Cowen | Maintains | Buy | — |
| 30 July 2026 | TD Cowen | Maintains | Buy | $260 → $275 |
| 21 July 2026 | Oppenheimer | Maintains | Outperform | $250 → $260 |
| 21 July 2026 | Oppenheimer | Maintains | Outperform | — |
| 20 July 2026 | Stifel | Maintains | Buy | $250 → $257 |
| 20 July 2026 | Stifel | Maintains | Buy | — |
| 16 July 2026 | RBC Capital | Maintains | Outperform | $252 → $261 |
| 16 July 2026 | RBC Capital | Maintains | Outperform | — |
| 2 June 2026 | Oppenheimer | Reiterates | Outperform | $242 → $250 |
| 2 June 2026 | Oppenheimer | Reiterates | Outperform | — |
| 30 Apr 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IEX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 26% of US stocks
Cheaper than 25% of US stocks
Cheaper than 17% of US stocks
Higher than 43% of US stocks
Higher than 47% of US stocks
Higher than 58% of US stocks
Higher than 81% of US stocks
Higher than 77% of US stocks
Higher than 70% of US stocks
Higher than 84% of US stocks
Higher than 30% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IDEX Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Idex (IEX) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade signals increased confidence in the company's near-term earnings potential.
Why it matters — A Zacks upgrade to Buy indicates improved analyst sentiment on Idex's earnings outlook, which IEX watchers would track as a signal of shifting market expectations.
Zacks Investment Research published a piece examining whether Idex (IEX) qualifies as a top pick for momentum investors, framing the company as a compelling momentum stock candidate. The article invites readers to assess IEX's momentum credentials.
Why it matters — A IEX watcher would care because the piece highlights the stock as a momentum opportunity, which could influence how investors view its recent trading performance.
IDEX reported second-quarter 2026 results that exceeded its expectations, driven by growth in its Health & Science Technologies segment, stronger orders and operational execution. The company raised its full-year outlook for organic sales growth, adjusted EBITDA margin and adjusted earnings per share.
Why it matters — The raised full-year outlook across multiple financial metrics signals improving operational momentum and stronger-than-anticipated demand in a key segment.
IDEX Corporation held its Q2 2026 earnings call, and the transcript was published by Seeking Alpha.
Why it matters — The earnings call transcript provides investors and analysts with detailed commentary on IDEX's second-quarter financial results, operations, and outlook.
Zacks Investment Research reported on Idex (IEX) Q2 2026 earnings, comparing key metrics to Wall Street estimates and year-ago actuals.
Why it matters — IEX watchers track these comparisons to gauge whether the company's quarterly performance is meeting, exceeding, or falling short of market expectations.
The 15 Wall Street analysts covering IDEX Corp. have a median 12-month price target of $258, with estimates ranging from $215 to $280. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering IDEX Corp., 9 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IDEX Corp. 85 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, IDEX Corp. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +10.1% from the last close, and Ticker Nerd's factor model ranks IDEX Corp. 85 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IDEX Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IEX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $215 to $280 over the next 12 months.
IDEX Corp. returned +46.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
IDEX Corporation is a global engineered products company that designs and manufactures specialized components and systems for critical industrial and scientific applications. The company focuses on providing mission‑critical solutions through three primary business segments: Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products.
The most recent item we track (Zacks Investment Research, 18 Aug 2026): "Idex (IEX) Upgraded to Buy: Here's Why". Idex (IEX) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade signals increased confidence in the company's near-term earnings potential.
IDEX Corporation is a global engineered products company that designs and manufactures specialized components and systems for critical industrial and scientific applications. The company focuses on providing mission‑critical solutions through three primary business segments: Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products. Its portfolio includes precision fluidics and optics for life science instrumentation, as well as pumps, valves, flow meters, compressors, and related equipment used by original equipment manufacturers and end users across sectors such as chemical processing, food and beverage, water, energy, and industrial infrastructure. In fire and safety markets, IDEX Corporation offers truck‑mounted fire pumps, valves, nozzles, monitoring and control systems, lighting, and hydraulic rescue tools that support emergency response, fire suppression, and municipal services. Headquartered in Northbrook, Illinois and operating through more than 50 businesses worldwide, IDEX Corporation plays an important role in enabling reliable processes in life sciences, industrial production, and public safety by supplying highly engineered, application‑specific products.
CEO Mr. Eric D. Ashleman · 8,700 employees · United States · https://www.idexcorp.com